2011
Pharmacotherapy for Primary CNS Lymphoma
Graber JJ, Omuro A. Pharmacotherapy for Primary CNS Lymphoma. CNS Drugs 2011, 25: 447-457. PMID: 21649446, DOI: 10.2165/11589030-000000000-00000.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaCNS lymphomaHigh-dose methotrexate-based chemotherapyMore effective chemotherapy regimensRefractory primary CNS lymphomaEffective chemotherapy regimensOptimal chemotherapy combinationReduced-dose radiotherapySingle-agent methotrexateMethotrexate-based chemotherapyStem cell rescueWhole brain radiotherapyHigh-dose chemotherapyLong-term remissionProgression-free survivalOngoing clinical trialsCombination of drugsChemotherapy regimensChemotherapy combinationsChemotherapy optionsRadiotherapy resultsSerious complicationsClinical trialsCell rescueConsolidation treatment
2006
Chemotherapy for primary central nervous system lymphoma.
Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurgical FOCUS 2006, 21: e12. PMID: 17134114, DOI: 10.3171/foc.2006.21.5.13.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaHigh-dose methotrexateUse of chemotherapyNervous system lymphomaElderly patientsSystem lymphomaSuch elderly patientsMainstay of treatmentToxic regimensChemotherapy regimensCorticosteroid agentsYounger patientsPatient ageRelapse rateRandomized trialsDifferent regimensOptimal treatmentRecent trialsTreatment paradigmHigh riskChemotherapyEffective drugsSingle agentRegimens
2005
Chemoradiotherapy for primary CNS lymphoma
Omuro AM, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma. Neurology 2005, 64: 69-74. PMID: 15642906, DOI: 10.1212/01.wnl.0000148641.98241.5e.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaLong-term outcomesComplete responsePartial responseCNS lymphomaMedian Karnofsky Performance Scale scoreMedian disease-free survivalProspective phase II trialKarnofsky Performance Scale scoreIncidence of neurotoxicityWhole brain radiotherapyMedian overall survivalDisease-free survivalPhase II trialYear of diagnosisPerformance Scale scoreChemotherapy regimenChemotherapy regimensFifteen patientsFirst relapseII trialMinor complicationsOverall survivalModality treatmentDisease progression